In vivo and in vitro experiments confirmed that a BCL2 inhibitor can induce the apoptosis of SCLC cell lines with high BCL2 levels, indicating that a BCL2 inhibitor may be effective for treating the ASCL1 subtype of SCLC [92]. Here, BCL2 is linked to small cell lung carcinoma.